Metronomic Chemotherapy in Oncology

Size: px

Start display at page:

Download "Metronomic Chemotherapy in Oncology"

Brooke Lang
5 years ago
Views:

1 Sixth International Meeting Metronomic Chemotherapy in Oncology Monday, October 1, 2018 and Tuesday, October, 2, a.m. to 6 p.m. 8 a.m. to 3:30 p.m. Michigan State University Grand Rapids Research Center 400 Monroe Avenue, NW Grand Rapids, MI 49503

2 Description and Objectives Following previous meetings held in Mumbai, Haifa, Marseille, Boston and Milan, the next workshop/meeting on metronomic chemotherapy will be held in Grand Rapids, Michigan, on October 1 and 2, Principal organizers are Drs. Nicolas Andre (France), Robert Kerbel (Canada) and Giselle Saulnier Sholler (United States). Recent promising updates regarding clinical trial results, including drug combinations, in a number of indications (e.g., breast, colorectal and ovarian cancers), as well as pediatric malignancies, will be summarized along with basic research advances, including immunotherapeutic, antiangiogenic and tumor cell targeting mechanisms mediated by metronomic chemotherapy. The conference is designed to highlight how to integrate angiogenesis and immunity, discuss emerging techniques and new strategies to identify and characterize precision targets, and facilitate national and international research coordination and collaboration among participants. Keynote Speakers Robert Kerbel, PhD, Canada Elisabetta Munzone, MD, Italy Anil Sood, MD, United States

3 Monday, October 1, a.m. to 8:30 a.m. Breakfast and Welcome 8:45 a.m. to 10:15 a.m. Preclinical: Angiogenesis/Immunity/Stem Cells Chair: Giselle Sholler, MD 10:15 a.m. to 10:30 a.m. Break Immunological response to anti-cancer therapy: lessons learned from MTD vs. LDM chemotherapy regimens Yuval Shaked, PhD Technion Integrated Cancer Center (TICC), Haifa, Israel Metronomic Targeting of Cancer Stem Cells Giselle Sholler, MD Helen DeVos Children s Hospital, United States A Novel Therapeutic Pillar, Anakoinosis: Tumor Tissue as a Multilevel Design Space Albrecht Reichler, MD, PhD Regensburg University Hospital, Regensburg, Germany Metronomic Chemotherapy-Based Regimens: Combination Versus Sequential Administration Giulio Francia, PhD University of Texas at El Paso, Texas, United States 10:30 a.m. to 11:15 a.m. Metronomic Chemotherapy: Looking Back, Looking Forward Keynote: Robert Kerbel, PhD University of Toronto, Toronto, Canada 11:15 a.m. to 11:45 a.m. Short Communications Traore Fouseiny, MD Gabriel Toure Hospital, Bamako, Mali 11:45 a.m. to 1 p.m. Lunch Irene Slavc, MD Medical University of Vienna, Austria continued

4 Monday, October 1, p.m. to 2:30 p.m. Preclinical: Pharmacology: Models/ Microenvironment/Nanotechnology 2:30 p.m. to 2:45 p.m. Break Metronomics for Triple Negative Breast Cancer Treatment Graciela Scharovsky, PhD National University of Rosario (UNR), Rosario, Argentina Metronomic chemotherapy in veterinary medicine: Opportunities to inform clinical translation Anthony Mutsaers, DVM, PhD Ontario Veterinary College, Guelph, Ontario, Canada High-Throughput Chemogenomics Identifies Novel Therapeutic Targets in Refractory Cancers: Toward Next-Generation Drug Repurposing Eddy Pasquier, PhD Marseille Cancer Research Center (CRCM), Marseille, France Metronomic Chemotherapy Enhances Anti-Tumor Efficacy by Sparing Tumor Stroma, Stemness and Immunity Kelvin Tsai, MD, PhD Taipei Medical University, National Health Research Institutes, Taipei, Taiwan 2:45 p.m. to 3:30 p.m. Metronomic Chemotherapy for Breast Cancer Clinical Experience Keynote: Elisabetta Munzone, MD European Institute of Oncology, Milano, Italy 3:30 p.m. to 3:45 p.m. Third Barton Kamen Prize 4 p.m. to 5:30p.m. Posters Session 5:30 p.m. Bus to Dinner 6 p.m. Welcome and Dinner continued

5 Tuesday, October 2, :30 a.m. to 7:30 a.m. Early Morning Metronomic Run Led by Nicolas Andre 8 a.m. to 8:30 a.m. Breakfast and Welcome 8:45 a.m.to 10:15 a.m. Clinical Therapies Session 1 Chair: Nicolas Andre, MD, PhD Hospital of Marseille (AP-HM), Marseille, France 10:15 a.m. to 10:30 a.m. Break Targeting Oncogenic MYCN With Low-Dose Metronomic Topotecan Preclinical Studies and Implications for the Clients Sabine Taschner-Mandl, PhD Children s Cancer Research Institute, Wien, Austria Topic to be Determined Shripad Banavali, MD Tata Memorial Center, Mumbai, India Metronomic Therapy in High-Risk Neuroblastoma Patients Frank Berthold, MD University Hospital of Cologne, Cologne, Germany Artificial Intelligence (AI)-enhanced combination metronomic chemotherapy Giannoula Lakka Klement, MD, FRCP (C) CSTS Health Care Inc. Toronto, Canada Metronomic Chemotherapy and Clonal Heterogeneity Nicolas Andre, MD, PhD Hospital of Marseille (APHM), Marseille, France 10:30 a.m. to 11:15 a.m. Metronomic Therapy: Lessons From the Lab and Clinic Keynote: Anil Sood, MD MD Anderson Cancer Center, Texas, USA 11:15 a.m. to 11:45 a.m. Short Communications Lina Ghibelli, PhD University of Rome, Rome, Italy 11:45 a.m. to 1 p.m. Lunch Jackie Kraveka, DO Medical University of South Carolina, South Carolina, United States continued

6 Tuesday, October 2, p.m. to 2:30 p.m. Clinical Therapies Session 2 Chair: TBD Gutta Cavat Lapidem: DEVEC Metronomic Schedule for Aggressive B and T Cell Lymphomas Christina Cox, MD Sant Andrea University Hospital, Rome, Italy Low-Dose Maintenance Chemotherapy in Rhabdomyosarcoma Daniel Orbach, MD Institut Curie, Paris, France Individualized Treatment of Children With High-Risk Solid Tumors in Real-Life Scenarios: Comparative Patient Series Analysis Michal Kyr, MD University Hospital Brno, Brno, Czech Republic Metronomic Low-Dose Cyclophosphamide for Advanced Metastatic Colorectal Cancer Andrew Godkin, MD, PhD Cardiff University, Cardiff, Wales Low-Dose Cyclophosphamide, Anti-Tumor T Cell Responses and the Role of Gut Bacteria Martin Scurr, Research Associate Cardiff University, Cardiff, Wales 2:30 p.m. to 3 p.m. Short Communications - to be determined 3 p.m. to 3:30 p.m. Conclusions and Farewell

Registration The registration fee includes tuition and

Academia, Industry, Organization, Individual: $200 Student,

7 Registration The registration fee includes tuition and materials for one attendee, breakfast, lunch and snacks. Academia, Industry, Organization, Individual: $200 Student, Postdoctorate: $50 To register for the event, please visit metronomics.org. Abstract Abstracts are due September 5, 2018 (300-word maximum) for selection of oral or poster presentation.

Cancer Metronomic Therapy Milan, February 26, 2016

Cancer Metronomic Therapy Milan, February 26, 2016 Metronomic Chemotherapy: Evolution and Development of the Concept Robert S. Kerbel, PhD Senior Scientist Sunnybrook Research Institute Professor, Dept.